Neurometa Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 3

Neurometa Therapeutics General Information

Description

Developer of neurodegenerative therapeutics designed to restore neuronal metabolism for disease modification. The company develops treatment candidates addressing metabolic dysfunction, fuel utilization imbalance, mitochondrial activity, and neurodegenerative disorder progression, enabling patients to access interventions targeting underlying biological mechanisms effectively.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • Novi Science Park
  • Niels Jernes Vej 10
  • 9220 Aalborg
  • Denmark
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Novi Science Park
  • Niels Jernes Vej 10
  • 9220 Aalborg
  • Denmark

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurometa Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Accelerator/Incubator 01-Jan-2023 Completed Generating Revenue
4. Early Stage VC Cancelled Generating Revenue
3. Accelerator/Incubator 10-Oct-2020 Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. Grant $80K Completed Generating Revenue
To view Neurometa Therapeutics’s complete valuation and funding history, request access »

Neurometa Therapeutics Patents

Neurometa Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4370129-A1 Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject Pending 12-Jul-2021
WO-2023285349-A1 Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject Inactive 12-Jul-2021
AU-2022269825-A1 Diazepane derivatives, processes for their preparation, and uses thereof for the amelioration, prevention and/or treatment of mental and neurological diseases Pending 04-May-2021
CA-3216365-A1 Diazepane derivatives, processes for their preparation, and uses thereof for the amelioration, prevention and/or treatment of mental and neurological diseases Pending 04-May-2021
EP-4334313-A1 Diazepane derivatives, processes for their preparation, and uses thereof for the amelioration, prevention and/or treatment of mental and neurological diseases Pending 04-May-2021 C07D417/14
To view Neurometa Therapeutics’s complete patent history, request access »

Neurometa Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurometa Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Nordic Mentor Network For Entrepreneurship Accelerator/Incubator
BioInnovation Institute Accelerator/Incubator Minority
SmiLe Incubator Accelerator/Incubator
To view Neurometa Therapeutics’s complete investors history, request access »

Neurometa Therapeutics FAQs

  • When was Neurometa Therapeutics founded?

    Neurometa Therapeutics was founded in 2019.

  • Where is Neurometa Therapeutics headquartered?

    Neurometa Therapeutics is headquartered in Aalborg, Denmark.

  • What is the size of Neurometa Therapeutics?

    Neurometa Therapeutics has 10 total employees.

  • What industry is Neurometa Therapeutics in?

    Neurometa Therapeutics’s primary industry is Drug Discovery.

  • Is Neurometa Therapeutics a private or public company?

    Neurometa Therapeutics is a Private company.

  • What is Neurometa Therapeutics’s current revenue?

    The current revenue for Neurometa Therapeutics is .

  • How much funding has Neurometa Therapeutics raised over time?

    Neurometa Therapeutics has raised $1.53M.

  • Who are Neurometa Therapeutics’s investors?

    Nordic Mentor Network For Entrepreneurship, BioInnovation Institute, and SmiLe Incubator have invested in Neurometa Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process